Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
for Squamous Cell Carcinoma
1 location in Pittsburgh
Sponsor: Christopher Wilke
Sex: All·Age: 18+
Code: NCT02128906·Phase 2·Recruiting·Listed May 2014